At the OnHelix conference in 2019 hosted by the Wellcome Trust, several speakers mentioned that in the future many diseases could be classified as rare. This is partly due to the fact that screening has become more accurate and sophisticated.
We work with several drug development/ pharmaceutical clients that have developed specific treatments for rare diseases. One of the recent translations we were involved in was translation was a monoclonal antibody treatment for mycosis fungoides (MF) or Sézary syndrome (SS). These documents were translated into several Nordic languages and had to meet EMA regulatory requirements.
The client required extremely competent and expert linguists to translate their dosing and administration guides in Finnish, Danish, Swedish and Norwegian. We were confident that our highly experienced linguist team could return excellent , fit for purpose translations. Our linguist team worked with our in-house project managers who were regularly liaising with the client to pin down the most accurate terminology and format for each of the markets.
Each translation had to meet EMA regulatory guidelines and all of our linguists are familiar with these formats.
Each document was around 10 pages in length and we were able to return all 4 translations – which had also been independently reviewed by other competent linguists- within a week.
The client was delighted with the work and said that they ‘rarely saw such good translation in this field’.
We were delighted with the feedback and passed this back to our team.
Translation is no exception to the rule that ‘perfection takes time’. This work took a lot of effort, cooperation and research that only comes from extensive experience and knowledge . Our specialist human linguist team all have this level of expertise.